 
        Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19
 
                                                    Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19
The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial
Eur J Integr Med. 2021 Feb; 42: 101305.Synopsis
Sixty patients with severe COVID-19 were randomized to receive routine care plus intravenous Xuebijing injection (n=30) or routine care alone (n=30) for the suppression of inflammatory response and management of symptoms. The primary outcome of interest was peripheral blood lymphocyte and interleukin (IL)-6 levels which were measured at 1, 7 and 14 days follow-up. Secondary outcomes of interest in...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
 
                Learn about our AI Driven 
 High Impact Search Feature
     
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue 
                     
                 
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         LOGIN
                                    LOGIN
                                 
            
Join the Conversation
Please Login or Join to leave comments.